Nitto Denko Avecia has announced the opening of their new manufacturing facility for oligonucleotide active pharmaceutical ingredients in Milford (MA, USA). The new 20,000 square feet expansion will provide more manufacturing and office space, allowing CGMP oligonucleotide manufacturing capacity up to 1.8mol. This expansion has more than doubled the company’s total capacity at the Milford site.
Detlef Rethage, the president of Nitto Denko Avecia, commented: “This expansion will help Avecia’s clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned. Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.”
Over the last 12 months, the new facility has created more than 120 additional jobs at the Milford site and will be formally opened with a ribbon cutting ceremony in August 2017.